Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 9Lymphoma 8Lymphoma, T-Cell, Cutaneous 4Mycosis Fungoides 3Recurrence 1Lymphomatoid Papulosis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Disease 1Dermatitis, Contact 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Mechlorethamine × Clear all
NCT00574496 2023-09-28

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
25 enrolled 10 charts
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡